Elbow Injury Clinical Trial
Official title:
Post-market Clinical Follow-up Study of the ExploRâ„¢ Radial Head System (Implants and Instrumentation) - A Retrospective Enrollment/Prospective Follow-Up Consecutive Series Study
Verified date | May 2024 |
Source | Zimmer Biomet |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
The objective of this retrospective and prospective consecutive series PMCF study is to collect long-term data confirming safety, performance and clinical benefits of the ExploR Radial Head System (implants and instrumentation) when used for radial head arthroplasty.
Status | Enrolling by invitation |
Enrollment | 93 |
Est. completion date | July 19, 2035 |
Est. primary completion date | August 16, 2024 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: Patient must have undergone primary elbow arthroplasty with the ExploR Radial Head System according to a cleared indication, which includes the following: - Replacement of the radial head for degenerative or post-traumatic disabilities presenting pain, crepitation and decreased motion at the radio-humeral and/or proximal radio-ulnar joint with: Joint destruction and/or subluxation visible on x-ray Resistance to conservative treatment - Primary replacement after fracture of the radial head - Symptomatic sequelae after radial head resection Patient must be 18 years of age or older. Patient must be willing and able to follow directions. Exclusion Criteria: - Infection - Sepsis - Osteomyelitis - Uncooperative patient or patient with neurological disorders who are incapable of following directions - Osteoporosis - Metabolic disorders which may impair bone formation - Osteomalacia - Distant foci of infections which may spread to implant site - Rapid joint destruction, marked bone loss or bone resorption apparent on roentgenogram - Patient is a prisoner. - Patient is a current alcohol or drug abuser. - Patient has a psychiatric illness or cognitive deficit that will not allow for proper informed consent - Patient is known to be pregnant or breastfeeding. - Patient is unwilling to sign informed consent. |
Country | Name | City | State |
---|---|---|---|
Norway | Akershus University Hospital | Lørenskog | |
United States | Norton Healthcare | Louisville | Kentucky |
Lead Sponsor | Collaborator |
---|---|
Zimmer Biomet |
United States, Norway,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Device Survivorship | Measured by recording and analyzing the incidence and frequency of revisions, complications and adverse events. Survivorship is calculated with Kaplan Meier. | 10 years | |
Primary | Device Safety | Assessed by recording frequency of adverse events during the length of the study. | 10 years | |
Secondary | QuickDASH | QuickDASH measures musculoskeletal pain and function of the arm. Higher scores indicate higher severity of disability. | 1, 3, 5, 7, and 10 years |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05552235 -
Assessment of the Safety and Performance of an Elbow Brace in the Prevention of Injuries During Sports Practice
|
N/A | |
Completed |
NCT03015415 -
The Posttraumatic Elbow Stiffness Treatment
|
N/A | |
Not yet recruiting |
NCT05687734 -
Outcome of Failed and Neglected Terrible Triad Injury of the Elbow
|
||
Not yet recruiting |
NCT05437133 -
Reliability and Validity of Self-reported Adherence to Elbow Orthosis Wearing Time
|
||
Completed |
NCT05870345 -
Pocket Sized Ultrasound (PsUS) and Pediatric Elbow Fractures
|
N/A | |
Not yet recruiting |
NCT05830201 -
The Presence of a Therapy Dog Reduces Pain and Anxiety During Pediatric Elbow Pin Removal
|
N/A | |
Withdrawn |
NCT03756155 -
Isometric Intervention for Lateral Elbow Tendinopathy
|
Phase 1/Phase 2 | |
Completed |
NCT01420887 -
Preservation of Joint Function Using Postoperative Continuous Passive Motion (CPM) A Pilot Study
|
N/A | |
Active, not recruiting |
NCT03582176 -
PrEvention of Posttraumatic Joint contractuRes With Ketotifen 2
|
Phase 3 |